Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SHE:300204)
China
· Delayed Price · Currency is CNY 25.70
-0.15 (-0.58%)
At close: Mar 9, 2026
SHE:300204 Revenue
Staidson (Beijing) BioPharmaceuticals had revenue of 54.94M CNY in the quarter ending September 30, 2025, a decrease of -30.10%. This brings the company's revenue in the last twelve months to 244.37M, down -30.32% year-over-year. In the year 2024, Staidson (Beijing) BioPharmaceuticals had annual revenue of 324.82M, down -10.81%.
Revenue (ttm)
244.37M
Revenue Growth
-30.32%
P/S Ratio
50.25
Revenue / Employee
496.68K
Employees
484
Market Cap
12.28B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 324.82M | -39.36M | -10.81% |
| Dec 31, 2023 | 364.18M | -184.81M | -33.66% |
| Jan 1, 2023 | 548.99M | -35.30M | -6.04% |
| Dec 31, 2021 | 584.29M | 159.08M | 37.41% |
| Dec 31, 2020 | 425.21M | -236.28M | -35.72% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chengdu Olymvax Biopharmaceuticals | 704.16M |
| InventisBio | 37.33M |
| Star Lake Bioscience Co., Inc.Zhaoqing Guangdong | 16.62B |
| Beijing Hotgen Biotech | 407.69M |
| Hualan Biological Vaccine | 976.44M |
| Pacific Shuanglin Bio-pharmacy | 2.38B |
| Mabwell (Shanghai) Bioscience | 662.52M |
| Chengzhi | 11.53B |